Attainment of Normal Lipid Levels Among Patients on Lipid-Modifying Therapy in Hong Kong

[1]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[2]  William Weintraub,et al.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.

[3]  B. Lask,et al.  Implications for Treatment , 2011 .

[4]  J. Paolini,et al.  Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. , 2010, Journal of clinical lipidology.

[5]  John B Buse,et al.  Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[6]  G. Nichols,et al.  Frequency of obtaining national cholesterol education program adult treatment panel III goals for all major serum lipoproteins after initiation of lipid altering therapy. , 2009, The American journal of cardiology.

[7]  P. Barter,et al.  Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[8]  Hyo‐Soo Kim,et al.  Flushing Profile of Extended-Release Niacin/Laropiprant at Initiation of Therapy in Asian Lipid Clinic Patients , 2009, Cardiology.

[9]  R. Pasternak,et al.  Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. , 2009, The American journal of cardiology.

[10]  G. Rosenhamer,et al.  Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. , 2009, Acta medica Scandinavica.

[11]  Stephen W. Gutkin,et al.  Effects of Modifying Triglycerides and Triglyceride-rich Lipoproteins on Cardiovascular Outcomes , 2008, Journal of cardiovascular pharmacology.

[12]  J. Redón,et al.  Serum lipid profiles and their relationship to cardiovascular disease in the elderly: the PREV-ICTUS study , 2008, Current medical research and opinion.

[13]  R. Collins,et al.  Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths , 2007, The Lancet.

[14]  Shah Ebrahim,et al.  Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) , 2007 .

[15]  Shah Ebrahim,et al.  Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) , 2007 .

[16]  Inder Singh,et al.  High-density lipoprotein as a therapeutic target: a systematic review. , 2007, JAMA.

[17]  E. van Ganse,et al.  Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study. , 2007, Clinical therapeutics.

[18]  H. Rodbard,et al.  American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. , 2007, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[19]  J. Gibbs,et al.  JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice , 2005, Heart.

[20]  Diabetes Uk,et al.  JBS 2: Joint British Societies9 guidelines on prevention of cardiovascular disease in clinical practice , 2005 .

[21]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[22]  Maria Inês Schmidt,et al.  The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. , 2005, Diabetes care.

[23]  J. Kastelein,et al.  Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. , 2005, Journal of the American College of Cardiology.

[24]  J. Chan,et al.  Association between adherence to statin therapy and lipid control in Hong Kong Chinese patients at high risk of coronary heart disease. , 2004, British journal of clinical pharmacology.

[25]  M. Rutter,et al.  C-Reactive Protein, the Metabolic Syndrome, and Prediction of Cardiovascular Events in the Framingham Offspring Study , 2004, Circulation.

[26]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[27]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[28]  T. Meade,et al.  Bezafibrate in men with lower extremity arterial disease: randomised controlled trial , 2002, BMJ : British Medical Journal.

[29]  J. Wittes,et al.  Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. , 2001, JAMA.

[30]  Bezafibrate Infarction Prevention study.  Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. , 2000, Circulation.

[31]  J. Chan,et al.  Obesity is the key determinant of cardiovascular risk factors in the Hong Kong Chinese population: cross-sectional clinic-based study. , 2000, Hong Kong medical journal = Xianggang yi xue za zhi.

[32]  W. Harris,et al.  n-3 fatty acids and serum lipoproteins: animal studies. , 1997, The American journal of clinical nutrition.

[33]  J. Hokanson,et al.  Plasma Triglyceride Level is a Risk Factor for Cardiovascular Disease Independent of High-Density Lipoprotein Cholesterol Level: A Metaanalysis of Population-Based Prospective Studies , 1996, Journal of cardiovascular risk.

[34]  L. Tenkanen,et al.  Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study , 1992 .

[35]  Vesa Manninen,et al.  Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study: Implications for Treatment , 1992, Circulation.

[36]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[37]  J. Stamler,et al.  Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.

[38]  J. Stamler.  Clofibrate and niacin in coronary heart disease. , 1975, JAMA.

[39]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[40]  G. Moneta.  Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: The National Health and Nutrition Examination Survey 2003-2004 , 2009 .

[41]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[42]  B. G. Brown,et al.  Safety considerations with niacin therapy. Commentary , 2007 .

[43]  W. Frishman.  Effects of longterm fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialKeech A, and the FIELD study investigators (Univ of Sydney, Australia; et al) Lancet 366:1849–1861, 2005§ , 2007 .

[44]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice , 2004 .

[45]  S. Grundy,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[46]  S. Haffner.  AMERICAN DIABETES ASSOCIATION. DYSLIPIDEMIA MANAGEMENT IN ADULTS WITH DIABETES , 2004 .

[47]  S. Haffner.  Dyslipidemia management in adults with diabetes. , 2004, Diabetes care.

[48]  Loyd,et al.  SIMVASTATIN AND NIACIN , ANTIOXIDANT VITAMINS , OR THE COMBINATION FOR THE PREVENTION OF CORONARY DISEASE , 2001 .

[49]  W. Harris,et al.  n-3 fatty acids and serum lipoproteins: human studies. , 1997, The American journal of clinical nutrition.

[50]  K. Anderson,et al.  Cardiovascular disease risk profiles. , 1991, American heart journal.